Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288704 · ClinicalTrials.gov registry record · Phase 3
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT00288704 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 104 participants.
The verdict
NCT00288704, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1). These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that stimulates the inflammatory process. IL-1 Trap (rilonacept) was designed to bind to the interleukin-1 cytokine and prevent it from binding to its receptors in the body.
Interventions
- DRUG Placebo
- DRUG rilonacept 160 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288704
The ClinicalTrials.gov registry entry for NCT00288704 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00288704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288704 about?
NCT00288704 is a clinical study titled "Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)". Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1). These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that stimulates the inflamm...
What is the current status of trial NCT00288704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2005-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00288704?
The interventions under investigation include: Placebo (DRUG), rilonacept 160 mg (DRUG).
Who is sponsoring clinical trial NCT00288704?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.